Xenon Pharmaceuticals (XENE) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

XENE Stock Forecast

Xenon Pharmaceuticals stock forecast is as follows: an average price target of $51.50 (represents a 32.56% upside from XENE’s last price of $38.85) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.

XENE Price Target

The average price target for Xenon Pharmaceuticals (XENE) is $51.50 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $60.00 to $46.00. This represents a potential 32.56% upside from XENE's last price of $38.85.

XENE Analyst Ratings

Buy

According to 11 Wall Street analysts, Xenon Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for XENE stock is 0 'Strong Buy' (0.00%), 11 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Xenon Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 10, 2024	Danielle Brill	Raymond James	$50.00	$39.42	26.84%	28.70%
Oct 01, 2024	Douglas Tsao	H.C. Wainwright	$53.00	$39.37	34.62%	36.42%
Aug 09, 2024	Laura Chico	Wedbush	$49.00	$41.05	19.37%	26.13%
Jun 18, 2024	Brian Abrahams	RBC Capital	$55.00	$36.25	51.72%	41.57%
Dec 14, 2022	-	Goldman Sachs	$60.00	$39.57	51.63%	54.44%
Nov 28, 2022	-	Wells Fargo	$50.00	$35.86	39.43%	28.70%
Nov 11, 2022	-	Guggenheim	$49.00	$35.00	40.00%	26.13%
Oct 18, 2022	Danielle Brill	Raymond James	$52.00	$35.52	46.40%	33.85%
Aug 11, 2022	-	Leerink Partners	$46.00	$39.68	15.93%	18.40%
Aug 10, 2022	-	RBC Capital	$46.00	$40.53	13.50%	18.40%

Row per page

Go to

The latest Xenon Pharmaceuticals stock forecast, released on Oct 10, 2024 by Danielle Brill from Raymond James, set a price target of $50.00, which represents a 26.84% increase from the stock price at the time of the forecast ($39.42), and a 28.70% increase from XENE last price ($38.85).

Xenon Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	2	4
Avg Price Target	-	$51.50	$51.75
Last Closing Price	$38.85	$38.85	$38.85
Upside/Downside	-100.00%	32.56%	33.20%

In the current month, the average price target of Xenon Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Xenon Pharmaceuticals's last price of $38.85. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 01, 2024	H.C. Wainwright	-	Buy	Initialise
Aug 09, 2024	Wedbush	Outperform	Outperform	Hold
Jun 18, 2024	RBC Capital	Outperform	Outperform	Hold
Nov 28, 2023	RBC Capital	Outperform	Outperform	Hold
Apr 25, 2023	Cantor Fitzgerald	-	Overweight	Initialise
Dec 14, 2022	Goldman Sachs	-	Buy	Initialise
Dec 12, 2022	Cowen & Co.	-	Outperform	Initialise
Nov 28, 2022	Wells Fargo	-	Overweight	Initialise
Nov 11, 2022	Guggenheim	Buy	Buy	Hold
Oct 18, 2022	Raymond James	Outperform	Buy	Initialise

Row per page

Go to

Xenon Pharmaceuticals's last stock rating was published by H.C. Wainwright on Oct 01, 2024. The company Initialise its XENE rating from "null" to "Buy".

Xenon Pharmaceuticals Financial Forecast

Xenon Pharmaceuticals Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Mar 17	Mar 16	Mar 15
Revenue	-	-	-	-	-	-	-	-	-	-	-	$5.38M	-	-	-	$8.77K	$132.00K	$536.00K	$8.77M	$3.74M	$8.12M	$2.22M	$4.36M	$5.15M	$6.55M	$13.38M	$7.08M	$16.00K	$601.00K	$4.01M
Avg Forecast	-	-	-	-	$1.51M	$978.30K	$669.10K	-	$357.14K	-	-	$2.30M	$1.56M	$461.54K	$615.38K	$2.91M	$4.15M	$4.18M	$7.74M	$5.69M	$10.22M	$2.72M	$2.97M	$3.21M	$11.66M	$6.90M	$4.50M	$14.48K	$548.74K	$1.87M
High Forecast	-	-	-	-	$1.51M	$978.30K	$669.10K	-	$357.14K	-	-	$2.30M	$1.56M	$461.54K	$615.38K	$2.91M	$4.15M	$4.18M	$7.74M	$5.69M	$10.22M	$2.72M	$2.97M	$3.21M	$11.66M	$6.90M	$4.50M	$17.37K	$658.49K	$2.25M
Low Forecast	-	-	-	-	$1.51M	$978.30K	$669.10K	-	$357.14K	-	-	$2.30M	$1.56M	$461.54K	$615.38K	$2.91M	$4.15M	$4.18M	$7.74M	$5.69M	$10.22M	$2.72M	$2.97M	$3.21M	$11.66M	$6.90M	$4.50M	$11.58K	$438.99K	$1.50M
# Analysts	-	-	-	-	4	3	4	-	8	-	-	9	4	6	4	3	7	4	3	4	7	4	4	4	6	7	9	14	11	14
Surprise %	-	-	-	-	-	-	-	-	-	-	-	2.34%	-	-	-	0.00%	0.03%	0.13%	1.13%	0.66%	0.79%	0.82%	1.47%	1.60%	0.56%	1.94%	1.57%	1.11%	1.10%	2.14%

Xenon Pharmaceuticals's average Quarter revenue forecast for Jun 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. XENE's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $5.38M (Dec 23).

Xenon Pharmaceuticals EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Mar 17	Mar 16	Mar 15
# Analysts	-	-	-	-	4	3	4	-	8	-	-	9	4	6	4	3	7	4	3	4	7	4	4	4	6	7	9	14	11	14
EBITDA	-	-	-	-	-	-	-	-	-	-	-	$-37.25M	$-55.68M	$-55.62M	$-50.89M	$-43.33M	$-35.09M	$-28.24M	$-13.93M	$-24.81M	$-15.44M	$-22.09M	$-15.64M	$-12.13M	$-8.89M	$107.00K	$-7.05M	$-7.35M	$-2.98M	$-4.02M
Avg Forecast	-	-	-	-	$-863.81K	$-561.43K	$-383.99K	-	$-204.96K	-	-	$-1.32M	$-896.14K	$-264.87K	$-353.16K	$-1.67M	$-2.47M	$-2.48M	$-20.47M	$-3.38M	$-6.08M	$-1.62M	$-16.00M	$-1.91M	$-6.94M	$-4.10M	$-9.25M	$-6.58M	$-2.70M	$-14.98M
High Forecast	-	-	-	-	$-863.81K	$-561.43K	$-383.99K	-	$-204.96K	-	-	$-1.32M	$-896.01K	$-264.87K	$-353.16K	$-1.67M	$-2.47M	$-2.48M	$-16.38M	$-3.38M	$-6.08M	$-1.62M	$-12.80M	$-1.91M	$-6.94M	$-4.10M	$-7.40M	$-5.26M	$-2.16M	$-11.99M
Low Forecast	-	-	-	-	$-863.81K	$-561.43K	$-383.99K	-	$-204.96K	-	-	$-1.32M	$-896.28K	$-264.87K	$-353.16K	$-1.67M	$-2.47M	$-2.48M	$-24.57M	$-3.38M	$-6.08M	$-1.62M	$-19.20M	$-1.91M	$-6.94M	$-4.10M	$-11.11M	$-7.89M	$-3.24M	$-17.98M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	28.26%	62.14%	210.01%	144.09%	25.98%	14.22%	11.37%	0.68%	7.34%	2.54%	13.68%	0.98%	6.35%	1.28%	-0.03%	0.76%	1.12%	1.11%	0.27%

6 analysts predict XENE's average Quarter EBITDA for Sep 20 to be $-6.94M, with a high of $-6.94M and a low of $-6.94M. This is -6581.53% lower than Xenon Pharmaceuticals's previous annual EBITDA (Jun 20) of $107.00K.

Xenon Pharmaceuticals Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Mar 17	Mar 16	Mar 15
# Analysts	-	-	-	-	4	3	4	-	8	-	-	9	4	6	4	3	7	4	3	4	7	4	4	4	6	7	9	14	11	14
Net Income	-	-	-	-	-	-	-	-	-	-	-	$-44.74M	$-48.46M	$-47.46M	$-41.73M	$-37.40M	$-37.15M	$-31.16M	$-19.67M	$-25.56M	$-15.45M	$-22.11M	$-15.76M	$-12.32M	$-8.86M	$-175.00K	$-7.48M	$-7.52M	$-3.26M	$-4.22M
Avg Forecast	$-83.52M	$-79.20M	$-77.19M	$-75.22M	$-69.59M	$-72.41M	$-69.55M	$-65.72M	$-66.01M	$-63.56M	$-54.38M	$-59.16M	$-60.31M	$-54.28M	$-48.39M	$-45.58M	$-40.39M	$-37.52M	$-20.90M	$-28.82M	$-29.77M	$-37.19M	$-16.13M	$-30.51M	$-8.43M	$-18.51M	$-9.82M	$-6.73M	$-2.95M	$-15.75M
High Forecast	$-83.52M	$-79.20M	$-77.19M	$-75.22M	$-69.59M	$-72.41M	$-69.55M	$-52.73M	$-44.76M	$-63.56M	$-54.38M	$-42.04M	$-60.31M	$-54.28M	$-48.39M	$-45.58M	$-40.39M	$-37.52M	$-16.72M	$-28.82M	$-29.77M	$-37.19M	$-12.90M	$-30.51M	$-8.43M	$-18.51M	$-7.86M	$-5.38M	$-2.36M	$-12.60M
Low Forecast	$-83.52M	$-79.20M	$-77.19M	$-75.22M	$-69.59M	$-72.41M	$-69.55M	$-71.83M	$-77.39M	$-63.56M	$-54.38M	$-77.07M	$-60.31M	$-54.28M	$-48.39M	$-45.58M	$-40.39M	$-37.52M	$-25.08M	$-28.82M	$-29.77M	$-37.19M	$-19.36M	$-30.51M	$-8.43M	$-18.51M	$-11.79M	$-8.07M	$-3.54M	$-18.90M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.76%	0.80%	0.87%	0.86%	0.82%	0.92%	0.83%	0.94%	0.89%	0.52%	0.59%	0.98%	0.40%	1.05%	0.01%	0.76%	1.12%	1.11%	0.27%

Xenon Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. XENE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Xenon Pharmaceuticals SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Mar 17	Mar 16	Mar 15
# Analysts	-	-	-	-	4	3	4	-	8	-	-	9	4	6	4	3	7	4	3	4	7	4	4	4	6	7	9	14	11	14
SG&A	-	-	-	-	-	-	-	-	-	-	-	$12.62M	$12.80M	$11.58M	$9.54M	$8.50M	$8.83M	$8.71M	$6.78M	$6.69M	$4.83M	$6.34M	$4.11M	$3.11M	$3.21M	$3.31M	$3.32M	$2.10M	$1.90M	$1.79M
Avg Forecast	-	-	-	-	$2.30M	$1.50M	$1.02M	-	$546.69K	-	-	$3.52M	$2.39M	$706.49K	$941.99K	$4.45M	$6.35M	$6.39M	$7.31M	$8.70M	$15.65M	$4.16M	$4.55M	$4.92M	$17.85M	$10.56M	$4.36M	$22.16K	$839.97K	$2.86M
High Forecast	-	-	-	-	$2.30M	$1.50M	$1.02M	-	$546.69K	-	-	$3.52M	$2.39M	$706.49K	$941.99K	$4.45M	$6.35M	$6.39M	$8.77M	$8.70M	$15.65M	$4.16M	$4.55M	$4.92M	$17.85M	$10.56M	$5.23M	$26.59K	$1.01M	$3.44M
Low Forecast	-	-	-	-	$2.30M	$1.50M	$1.02M	-	$546.69K	-	-	$3.52M	$2.39M	$706.49K	$941.99K	$4.45M	$6.35M	$6.39M	$5.85M	$8.70M	$15.65M	$4.16M	$4.55M	$4.92M	$17.85M	$10.56M	$3.49M	$17.72K	$671.98K	$2.29M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	3.59%	5.36%	16.40%	10.12%	1.91%	1.39%	1.36%	0.93%	0.77%	0.31%	1.52%	0.90%	0.63%	0.18%	0.31%	0.76%	94.77%	2.26%	0.62%

Xenon Pharmaceuticals's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to XENE last annual SG&A of $12.62M (Dec 23).

Xenon Pharmaceuticals EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Mar 17	Mar 16	Mar 15
# Analysts	-	-	-	-	4	3	4	-	8	-	-	9	4	6	4	3	7	4	3	4	7	4	4	4	6	7	9	14	11	14
EPS	-	-	-	-	-	-	-	-	-	-	-	$-0.00	$-0.00	$-0.00	$-0.63	$-0.57	$-0.57	$-0.55	$-0.36	$-0.62	$-0.36	$-0.51	$-0.42	$-0.33	$-0.25	$-0.00	$-0.22	$-0.42	$-0.23	$-0.30
Avg Forecast	$-1.07	$-1.02	$-0.99	$-0.97	$-0.89	$-0.93	$-0.89	$-0.84	$-0.85	$-0.82	$-0.70	$-0.76	$-0.77	$-0.70	$-0.62	$-0.58	$-0.52	$-0.48	$-0.41	$-0.37	$-0.38	$-0.48	$-0.43	$-0.39	$-0.11	$-0.24	$-0.32	$-0.34	$-0.19	$0.52
High Forecast	$-1.07	$-1.02	$-0.99	$-0.97	$-0.89	$-0.93	$-0.89	$-0.68	$-0.57	$-0.82	$-0.70	$-0.54	$-0.77	$-0.70	$-0.62	$-0.58	$-0.52	$-0.48	$-0.41	$-0.37	$-0.38	$-0.48	$-0.43	$-0.39	$-0.11	$-0.24	$-0.32	$-0.27	$-0.15	$0.63
Low Forecast	$-1.07	$-1.02	$-0.99	$-0.97	$-0.89	$-0.93	$-0.89	$-0.92	$-0.99	$-0.82	$-0.70	$-0.99	$-0.77	$-0.70	$-0.62	$-0.58	$-0.52	$-0.48	$-0.41	$-0.37	$-0.38	$-0.48	$-0.43	$-0.39	$-0.11	$-0.24	$-0.32	$-0.41	$-0.23	$0.42
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.00%	0.00%	0.00%	1.01%	0.97%	1.10%	1.14%	0.89%	1.67%	0.94%	1.07%	0.97%	0.85%	2.30%	0.02%	0.68%	1.24%	1.21%	-0.58%

According to undefined Wall Street analysts, Xenon Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to XENE previous annual EPS of $NaN (undefined).

Xenon Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VTYX	Ventyx Biosciences	$1.78	$33.86	1802.25%	Buy
LYEL	Lyell Immunopharma	$1.11	$6.67	500.90%	Hold
FIXX	Q32 Bio	$0.93	$2.70	190.32%	Buy
ANAB	AnaptysBio	$19.97	$52.00	160.39%	Buy
REPL	Replimune Group	$10.95	$24.20	121.00%	Buy
KRON	Kronos Bio	$0.85	$1.63	91.76%	Buy
KROS	Keros Therapeutics	$53.62	$102.60	91.35%	Buy
VRDN	Viridian Therapeutics	$20.24	$37.92	87.35%	Buy
IDYA	IDEAYA Biosciences	$25.86	$46.58	80.12%	Buy
MRUS	Merus	$43.49	$77.13	77.35%	Buy
CYTK	Cytokinetics	$51.09	$83.23	62.91%	Buy
ASND	Ascendis Pharma	$124.44	$190.21	52.85%	Buy
MGTX	MeiraGTx	$5.98	$9.00	50.50%	Buy
DYN	Dyne Therapeutics	$29.68	$43.88	47.84%	Buy
EWTX	Edgewise Therapeutics	$31.51	$45.00	42.81%	Buy
PCVX	Vaxcyte	$87.08	$124.00	42.40%	Buy
XENE	Xenon Pharmaceuticals	$38.85	$51.50	32.56%	Buy
CRNX	Crinetics Pharmaceuticals	$55.17	$70.14	27.13%	Buy
DICE	DICE Therapeutics	$47.55	$60.00	26.18%	Buy
NUVL	Nuvalent	$91.06	$111.57	22.52%	Buy
UTHR	United Therapeutics	$360.71	$358.20	-0.70%	Buy
ACLX	Arcellx	$87.59	$83.00	-5.24%	Buy
KRTX	Karuna Therapeutics	$329.83	$257.50	-21.93%	Buy

XENE Forecast FAQ

Is Xenon Pharmaceuticals a good buy?

Yes, according to 11 Wall Street analysts, Xenon Pharmaceuticals (XENE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 100.00% of XENE's total ratings.

What is XENE's price target?

Xenon Pharmaceuticals (XENE) average price target is $51.5 with a range of $46 to $60, implying a 32.56% from its last price of $38.85. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Xenon Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for XENE stock, the company can go up by 32.56% (from the last price of $38.85 to the average price target of $51.5), up by 54.44% based on the highest stock price target, and up by 18.40% based on the lowest stock price target.

Can Xenon Pharmaceuticals stock reach $60?

XENE's average twelve months analyst stock price target of $51.5 does not support the claim that Xenon Pharmaceuticals can reach $60 in the near future.

What are Xenon Pharmaceuticals's analysts' financial forecasts?

Xenon Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.15M (high $3.15M, low $3.15M), average EBITDA is $-1.809M (high $-1.809M, low $-1.809M), average net income is $-277M (high $-264M, low $-283M), average SG&A $4.83M (high $4.83M, low $4.83M), and average EPS is $-3.558 (high $-3.391, low $-3.636). XENE's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-315M (high $-315M, low $-315M), average SG&A $0 (high $0, low $0), and average EPS is $-4.044 (high $-4.044, low $-4.044).

Did the XENE's actual financial results beat the analysts' financial forecasts?

Based on Xenon Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $9.43M, which missed the average analysts forecast of $18.97M by -50.27%. Apple's EBITDA was $-129M, beating the average prediction of $-27.094M by 376.65%. The company's net income was $-125M, missing the average estimation of $-144M by -13.17%. Apple's SG&A was $32.81M, beating the average forecast of $24.5M by 33.89%. Lastly, the company's EPS was $-2.07, beating the average prediction of $-1.993 by 3.84%. In terms of the last quarterly report (Dec 2023), Xenon Pharmaceuticals's revenue was $5.38M, beating the average analysts' forecast of $2.3M by 134.21%. The company's EBITDA was $-37.249M, beating the average prediction of $-1.318M by 2725.61%. Xenon Pharmaceuticals's net income was $-44.743M, missing the average estimation of $-59.162M by -24.37%. The company's SG&A was $12.62M, beating the average forecast of $3.52M by 258.88%. Lastly, the company's EPS was $-0.0007, missing the average prediction of $-0.759 by -99.91%